US equities
|
NVDA
$238.90
▲+2.12%
SPCX
$171.09
▲+7.63%
MU
$1,063.96
▼-1.02%
TSLA
$378.73
▲+2.20%
WBD
$30.95
▲+0.03%
MSFT
$525.18
▲+1.48%
AAPL
$332.89
▼-0.24%
META
$741.90
▲+1.90%
NVDA
$238.90
▲+2.12%
SPCX
$171.09
▲+7.63%
MU
$1,063.96
▼-1.02%
TSLA
$378.73
▲+2.20%
WBD
$30.95
▲+0.03%
MSFT
$525.18
▲+1.48%
AAPL
$332.89
▼-0.24%
META
$741.90
▲+1.90%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Lexaria Bioscience Corp. - Common Stock
(NQ:
LEXX
)
2.770
-0.110 (-3.82%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Lexaria Bioscience Corp. - Common Stock
< Previous
1
2
...
14
15
16
17
18
19
20
21
22
...
32
33
Next >
Lexaria’s DehydraTECH-CBD(TM) Enhances Performance Compared to Epidiolex(R) in Seizure Study Program
November 29, 2022
Via
ACCESSWIRE
Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Investigation of DehydraTECH-CBD’s Potential Therapeutic Value for Diabetes and Defmentia with New Studies
November 29, 2022
Via
Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Launches Animal Study to Evaluate Potential Therapeutic Effect of DehydraTECH-CBD on Dementia
November 23, 2022
Via
Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Focus on Dementia and Diabetes Featured in New Interview
November 21, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Lexaria's Human Clinical Hypertension Study a Success
October 27, 2022
Via
ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Focus on Dementia and Diabetes Featured in New Interview
November 21, 2022
Via
CannabisNewsWire
Topics
Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Kicks Off First-Ever Study on DehydraTECH-CBD for the Potential Treatment of Diabetes
November 21, 2022
Via
Investor Brand Network
Lexaria Bioscience Turns Focus to Dementia and Diabetes with New Studies
November 21, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Potential Hypertension Treatment Poised to Provide Reprieve to Millions of Patients
November 18, 2022
Via
Investor Brand Network
Topics
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Potential Hypertension Treatment Poised to Provide Reprieve to Millions of Patients
November 18, 2022
Via
CannabisNewsWire
Topics
Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Approved to Proceed with Human Study Evaluating Effectiveness of Patented DehydraTECH(TM) Technology in Boosting Oral-Tissue Absorption of Nicotine
November 17, 2022
Via
CannabisNewsWire
Lexaria Bioscience Corp. (NASDAQ: LEXX) Approved to Proceed with Human Study Evaluating Effectiveness of Patented DehydraTECH(TM) Technology in Boosting Oral-Tissue Absorption of Nicotine
November 17, 2022
Via
Investor Brand Network
Zacks SCR Uses Lexaria Bioscience Corp. (NASDAQ: LEXX) HYPER-H21-4 Study to Support $15 Share Valuation
November 11, 2022
Via
Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces First-Ever Study Exploring Therapeutic Use of DehydraTECH-CBD in Dementia
November 10, 2022
Via
Investor Brand Network
Topics
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces First-Ever Study Exploring Therapeutic Use of DehydraTECH-CBD in Dementia
November 10, 2022
Via
CannabisNewsWire
Topics
Intellectual Property
Lexaria Examining Potential Therapeutic Use of DehydraTECH-CBD in Dementia
November 10, 2022
Via
ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Commences 1st-Ever Study Evaluating DehydraTECH-CBD’s Effect on Diabetes
November 08, 2022
Via
Investor Brand Network
Topics
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Commences 1st-Ever Study Evaluating DehydraTECH-CBD’s Effect on Diabetes
November 08, 2022
Via
CannabisNewsWire
Topics
Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Aiming to Address Unmet Patient Needs of Hypertensive Patients
November 08, 2022
Via
Investor Brand Network
Lexaria Starts Study Evaluating the Effect of DehydraTECH-CBD on Diabetes
November 08, 2022
Via
ACCESSWIRE
This BioTech Company Using CBD For Enhanced Hypertension Treatment Could Be One To Watch
↗
November 07, 2022
Lexaria Bioscience Corp.
Via
Benzinga
Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Zero Adverse Effects from Successful HYPER-H21-4 Study of DehydraTECH(TM)-CBD for High Blood Pressure
November 04, 2022
Via
Investor Brand Network
Topics
Death
Lexaria Bioscience Corp. (NASDAQ: LEXX) Maintains Late 2022/Early 2023 for Full IND Application for DehydraTECH-CBD
November 02, 2022
Via
Investor Brand Network
TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Secures IRB Approval for Human Clinical Nicotine Study
November 01, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Lexaria Receives Independent Review Board Approval for its Upcoming Human Oral Nicotine Study
November 01, 2022
Via
ACCESSWIRE
Lexaria Bioscience Corp. (NASDAQ: LEXX) Moves to Address Adverse Effects of Hypertension with DehydraTECH(TM) – CBD
October 31, 2022
Via
Investor Brand Network
TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Successful Results of Human Clinical Hypertension Study
October 27, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Potential Hypertension Medication Poised to Reduce Risk of Blood-Pressure-Induced Dementia, Cognitive Decline
October 25, 2022
Via
Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Holds Potential to Represent Multiple Commercial Opportunities
October 21, 2022
Via
Investor Brand Network
Topics
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Holds Potential to Represent Multiple Commercial Opportunities
October 21, 2022
Via
CannabisNewsWire
Topics
Intellectual Property
< Previous
1
2
...
14
15
16
17
18
19
20
21
22
...
32
33
Next >
